Amy S. Babiuch

Amy S. Babiuch

Auto-generated profile, based on publicly available information

Amy S. Babiuch

Center for Ophthalmic Bioinformatics, Cole Eye Institute (S.B.K. and M.Y.Z.), Cleveland Clinic, Cleveland, Ohio, USA; Department of Ophthalmology (K.C.A., A.S.B. and K.E.T.), Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, USA; Department of Medical Education (A.S.B. and K.E.T.), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2025 in Ophthalmology Retina
Verified
Journal Article
Open access
SBSuraj Bala
Suraj Bala
GBGabriel C.S. Barbosa
Gabriel C.S. Barbosa
NMNitesh Mohan
Nitesh Mohan
SSSunil K. Srivastava
Sunil K. Srivastava
PKPeter K. Kaiser
Peter K. Kaiser
DMDanny Mammo
Danny Mammo
To evaluate the short-term outcomes of patients with exudative neovascular age-related macular degeneration (nAMD) treated with high-dose aflibercept 8.0 mg (HDA), focusing on anatomical and functional changes, as well as the feasibility of extending treatment intervals in real-world clinical practice. Retrospective, noncomparative cohort study. 219 eyes from 184 patients with nAMD who received at least three HDAs between August 2023 and October 2024. Patients included in this study were either treatment-naïve or had been previously treated with other anti-VEGF agents. Clinical outcomes, including best-corrected visual acuity (BCVA) and macular OCT parameters, were evaluated at baseline and after each HDA. The primary outcome was the proportion of eyes able to sustain an 8 ± 1 week or longer treatment interval without anatomical deterioration. Secondary outcomes included anatomical and functional changes. The average follow-up time was 22.9 ± 4.9 weeks. 209 eyes (95.4%) were previously treated, and 10 eyes (4.6%) were treatment-naïve. After the first three injections, 206 eyes (94.1%) received a fourth HDA and 70 eyes (31.9%) received a fifth HDA. 102 eyes (46.6%) of the total cohort with an interval shorter than 8 weeks after three initial injections had persistent macular fluid. 24 eyes (11.0%) were switched to another anti-VEGF agent. Overall, the mean BCVA was 61.9 ± 21.7 ETDRS letters at baseline and 61.7 ± 22.6 at the final visit, with no statistically significant difference observed (p = 0.934). Central subfield thickness and pigment epithelial detachment height remained stable. Significant reductions were observed in subretinal (54.3% to 41.1%, p = 0.006) and intraretinal fluid (53.9% to 39.3%, p = 0.002). Among previously treated eyes, the mean pre-switch treatment interval was 5.8 ± 2.5 weeks and increased to 7.4 ± 2.2 weeks after the three initial injections (p < 0.0001). HDA demonstrated stable BCVA and significant reductions in macular fluid during the follow-up period. A considerable proportion of patients were unable to extend treatment intervals to at least 8-weeks due to persistent macular fluid. These findings suggest that HDA maintains functional stability while improving anatomic outcomes, though real-world challenges in managing chronic nAMD may limit the ability to extend treatment intervals.

19 August 2020 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Open access
PDF file
JAJoseph R. Abraham
Joseph R. Abraham
JBJoseph Boss
Joseph Boss
ABAmy S. Babiuch
Amy S. Babiuch
RSRishi P. Singh
Rishi P. Singh
SSSunil Srivastava
Sunil Srivastava
Justis P. EhlersJustis P. Ehlers
Justis P. Ehlers
This work evaluated the longitudinal dynamics of ellipsoid zone (EZ) integrity in retinal vein occlusion (RVO) with macular edema and their relation to outcomes. Clinical characteristics and optical coherence tomography data of patients with RVO and associated macular edema were collected at baseline and at 3 and 12 months. Macular cube scans were exported into EZ and retinal-layer analysis software. Longitudinal EZ parameters and visual acuity (VA) outcomes were regressed and correlated. The study included 108 eyes of 108 patients; all eyes were treated with antivascular endothelial growth factor therapy at the baseline visit. VA improved from 20/97 at baseline to 20/52 at 3 months and 12 months (P < .001), correlating with EZ integrity at each time point (P < .001). At 12 months following initiation of antivascular endothelial growth factor therapy, EZ partial attenuation and EZ total attenuation improved over 12 months from 16.4% to 8.5% (P < .001) and from 12.3% to 5.9% (P < .001), respectively. VA improvement from baseline to 12 months correlated with improvement of EZ partial and total attenuation (P < .001). Baseline EZ characteristics did not predict VA outcomes, but at 3 months, EZ parameters did predict improvement in visual outcomes by 12 months (P < .01). EZ and outer retinal integrity are correlated with functional outcomes in RVO. Following treatment, EZ integrity improves and is associated with functional improvement. In RVO baseline, EZ features were not associated with 1-year VA outcomes, but evaluation of EZ integrity at 3 months was linked to 1-year outcomes.

1 November 2020 in Optometry and Vision Science
Verified
Journal Article
Closed access
CMChristopher Maatouk
Christopher Maatouk
FHFiras Ba Hentati
Firas Ba Hentati
CUCatherine A. Ba Urbano
Catherine A. Ba Urbano
TGTyler E. Do Greenlee
Tyler E. Do Greenlee
TCThais F. Conti
Thais F. Conti
RSRishi P. Singh
Rishi P. Singh

15 July 2020 in Ophthalmic Genetics
Verified
Journal Article
Closed access
KWKevin Wang
Kevin Wang
BSBrittney Statler
Brittney Statler
MRMichael Ramos
Michael Ramos
MDMeghan J DeBenedictis
Meghan J DeBenedictis
ABAmy Babiuch
Amy Babiuch
ETElias I. Traboulsi
Elias I. Traboulsi
To report the case of a patient with two distinct genetic systemic diseases – pseudoxanthoma elasticum (PXE) and Usher syndrome – confirmed by genetic testing. Single Retrospective Case Report A 36-year-old woman presented with acute central vision loss of the left eye (OS). Fundus exam revealed choroidal neovascularization OS in the setting of angioid streaks secondary to an underlying diagnosis of PXE. Unexpectedly, she also exhibited peripheral bony spicules with significant visual field constriction. Physical exam revealed skin papules on her neck and hearing loss. The presence of angioid streaks and skin findings was compatible with PXE; the etiology of her pigmentary retinopathy and hearing loss was elucidated using genetic testing. The patient was found to be compound heterozygous for pathogenic variants in both the ABCC6 and USH2A genes, confirming the diagnosis of two rare disorders in a single patient. PXE and Usher syndrome are rare systemic disorders that cause distinctive retinal abnormalities. This report highlights the importance of genetic testing in diagnosing uncommon hereditary retinal disorders and outlines the progression of disease over 6 years.

25 July 2017 in Journal of Vitreoretinal Diseases
Verified
Journal Article
Closed access
JYJason M. Young
Jason M. Young
KWKaren M. Wai
Karen M. Wai
FSFabiana Q. Silva
Fabiana Q. Silva
FCFelipe F. Conti
Felipe F. Conti
SSSunil K. Srivastava
Sunil K. Srivastava
RSRishi P. Singh
Rishi P. Singh
To evaluate long-term visual and anatomical outcomes of anti–vascular endothelial growth factor (VEGF) therapy for macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. Patients with ME secondary to hemi-RVO (HRVO), central RVO (CRVO), or branch RVO (BRVO) after initiating anti-VEGF therapy were followed for at least 36 months. Main outcomes were change in best visual acuity (BVA) and mean absolute change in central subfield thickness (CST) at 12, 24, 36, and 48 months. Patients with BRVO showed significant increases in BVA that were maintained after 12, 24, 36, and 48 months (+11.03, +12.06, +10.71, and +9.26 letters, respectively; P < .05). CST significantly decreased after 12, 24, 36, and 48 months (−83.51, −67.93, −97.52, −127.85 µm, respectively; P < .05). In patients with CRVO/HRVO, significant improvements in BVA were seen at 12 and 24 months (+9.39 and +8.54 letters, respectively; P = .023). At 36 and 48 months, the visual gain was not significant (+2.64 and +3.42 letters, respectively; P > .05). For CST changes, there were significant decreases at 12, 24, and 36 months (−146.23, −149.54, and −166.44 µm, respectively; P < .05). At 48 months (−97.66 µm, P = .130), changes in CST were not significant. In routine clinical practice, visual and anatomical benefits of anti-VEGF agents in patients with BRVO were sustained at 36 and 48 months. For patients with CRVO/HRVO, anatomical improvements were maintained for 36, but not 48 months, while visual improvements were no longer maintained by 36 months.

11 July 2026 in American Journal of Ophthalmology
Verified
Journal Article
Open access
SKSonia B. Kim
Sonia B. Kim
MZMelody Y. Zhou
Melody Y. Zhou
KAKevin C. Allan
Kevin C. Allan
DKDavid . Kaelber
David . Kaelber
ABAmy S. Babiuch
Amy S. Babiuch
KTKatherine E. Talcott
Katherine E. Talcott
To investigate how exposure to GABAergic medications affects diabetic retinopathy (DR) development, progression, and complications. Retrospective clinical cohort study using multi-institutional electronic health record data (TriNetX, US Collaborative Network). Adults aged ≥ 18 years with type 2 diabetes mellitus with ophthalmology follow-up. Study cohorts had GABAergic prescription records for 6-months, 1-year, 3-years, or 5-years; control cohorts had no GABAergic prescriptions ever. Cohorts were propensity-score matched (PSM) on demographics, systemic comorbidities, common indications for GABAergic medications, and ophthalmic confounders. Outcomes included incident DR, progression from mild/moderate nonproliferative DR to severe nonproliferative DR, proliferative DR, or interventions required in advanced DR, and incident DR complications. Hazard ratio (HR) and 95% confidence intervals (CI); significance threshold < 0.9 or > 1.1. After successful PSM, there were 110 495 (6-months), 99 187 (1-year), 63 194 (3-years), and 40 810 (5-years) DR-naive study patients with the respective GABAergic prescription durations of interest. Compared to 109 603 DR-naive control patients, study patients demonstrated a significantly reduced HR for DR development at all time points from 6-months (HR 0.61, 95% CI 0.57-0.65) to 5-years (HR 0.81, 95% CI 0.77-0.85). Study patients (n = 14 644) with baseline mild/moderate nonproliferative DR had a significantly reduced hazard of progressing to severe nonproliferative DR, proliferative DR, or DR interventions with 6-months (HR 0.75, 95% CI 0.68-0.82) and 1-year (HR 0.69, 95% CI 0.73, 0.86) GABAergic exposure. Prescription for 6-months (HR 0.74, 95% CI 0.68-0.80) to 3-years (HR 0.80, 95% CI 0.84-0.86) was associated with a significantly reduced hazard for DR complications. Stratification by 4 specific medication indications consistently showed a reduced hazard for DR development with a 6-month prescription duration. GABAergic medication use, particularly short-term exposure, is associated with a reduced hazard of DR development, progression, and complications. These exploratory findings support a potential role of GABAergic modulation in diabetic retinal disease.